Calithera Biosciences, a clinical-stage pharma company focused on small molecule drugs against tumor metabolism and immunology targets to treat cancer, has achieved pharmacokinetic and pharmacodynamic goals for CB-1158 under its agreement with Incyte Corp., triggering a $12 million payment from Incyte. “We are very excited to achieve this early milestone under our collaboration with Incyte as CB-1158 has demonstrated the desired pharmacologic activity in humans, with a corresponding elevatio...